Twist Bioscience (TWST)
Writes synthetic DNA on silicon for sequencing workflows, biological research, and antibody discovery.
$159.26
vs last close−5.34 (−3.24%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Sep 2023 | Q1 FY24Dec 2023 | Q2 FY24Mar 2024 | Q3 FY24Jun 2024 | Q4 FY24Sep 2024 | Q1 FY25Dec 2024 | Q2 FY25Mar 2025 | Q3 FY25Jun 2025 | Q4 FY25Sep 2025 | Q1 FY26Dec 2025 | Q2 FY26Mar 2026 | Q3 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 71 | 75 | 81 | 85 | 89 | 93 | 96 | 99 | 104 | 111 | 118 |
| Cost of revenue | 42 | 43 | 44 | 46 | 46 | 46 | 47 | 45 | 48 | 50 | 54 | 56 |
| Gross profit | 25 | 29 | 31 | 35 | 38 | 43 | 46 | 51 | 51 | 54 | 57 | 62 |
| 75 | 76 | 80 | 124 | 74 | 77 | 88 | 81 | 81 | 87 | 96 | 99 | |
| Research & development | 24 | 23 | 24 | 22 | 21 | 21 | 24 | 18 | 17 | 17 | 20 | 18 |
| 47 | 53 | 56 | 57 | 53 | 56 | 64 | 63 | 64 | 70 | 76 | 81 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 0 | 0 | 0 |
| Other expenses | 3 | 0 | 0 | 45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −50 | −47 | −49 | −89 | −36 | −35 | −42 | −30 | −30 | −33 | −39 | −36 |
| 4 | 4 | 4 | 4 | 1 | 3 | 2 | 51 | 3 | 3 | −5 | 2 | |
| Interest income | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −4 | −4 | −4 | −4 | −1 | −3 | −3 | −51 | −3 | 0 | 0 | −2 |
| Income before tax | −46 | −43 | −45 | −85 | −35 | −31 | −39 | 21 | −27 | −30 | −44 | −35 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −46 | −43 | −45 | −86 | −34 | −32 | −39 | 20 | −27 | −31 | −44 | −34 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| Net income | −46 | −43 | −45 | −86 | −35 | −32 | −39 | 20 | −27 | −31 | −44 | −35 |
| EPS, basic | −$0.81 | −$0.75 | −$0.79 | −$1.47 | −$0.60 | −$0.53 | −$0.66 | $0.34 | −$0.45 | −$0.50 | −$0.71 | −$0.56 |
| EPS, diluted | −$0.81 | −$0.75 | −$0.79 | −$1.47 | −$0.60 | −$0.53 | −$0.66 | $0.33 | −$0.45 | −$0.50 | −$0.71 | −$0.56 |
| Weighted average shares, basic | 57 | 57 | 58 | 58 | 58 | 59 | 60 | 60 | 60 | 61 | 62 | 62 |
| Weighted average shares, diluted | 57 | 57 | 58 | 58 | 58 | 59 | 60 | 61 | 60 | 61 | 62 | 62 |
| EBITDA | −38 | −35 | −37 | −77 | −28 | −25 | −33 | 26 | −21 | −27 | −32 | −28 |
| Depreciation & amortization | 9 | 8 | 8 | 8 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 7 |
| EBIT | −46 | −43 | −45 | −85 | −35 | −31 | −39 | 21 | −27 | −33 | −39 | −35 |
